Caris Life Sciences, a molecular science and technology company developing innovative healthcare solutions, and Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, entered into a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare’s therapeutic programs into clinical trials through advanced molecular profiling approaches that guide patient selection and participation.

Flare will leverage Caris’ next generation sequencing technology for the molecular testing of patients treated with Flare’s assets. In addition, Flare will receive access to Caris’ data insights and analytics capabilities to accelerate oncology drug discovery, identify novel biomarkers and optimize clinical positioning strategies for their pipeline. Flare will also leverage Caris’ biomarker-driven patient selection for clinical trials, allowing Caris the first option to develop a companion diagnostic for any drug candidate developed as part of the collaboration.

“We understand the importance of shaping translational insights early on as a major area of focus to help ensure efficient drug development at scale and clinical trial preparedness,” said Michaela Bowden, chief development officer at Flare. “With access to Caris’ robust clinico-genomic real-world data, comprehensive molecular profiling and extensive precision oncology alliance network, we are well positioned to unlock the full potential of drugging transcription factors by further unraveling the molecular complexities of cancer at the patient level and successfully enter the next phase of our growth as a clinical stage company.”

“This broad partnership with Flare will leverage Caris’ leading molecular science and technology solutions to support Flare’s novel approach to decipher the biology of transcription factors to develop small molecule medicines,” said Milan Radovich, senior vice president and chief scientific officer, Caris Life Sciences. “The data accessibility and continuum across real world and clinical trial populations will provide Flare the necessary insights for successful molecule discovery and development.”